Decoy Therapeutics Inc. SEC filings DCOY
Decoy Therapeutics Inc. has 743 filings in SEC EDGAR's recent list, going back to Aug 6, 2014. Its latest annual report, Form 10-K, was filed on Mar 31, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 23, 2026 (material agreement, unregistered share sale, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Oct 16, 2026 | — |
| EFFECT | Filing | Jul 17, 2026 | — |
| EFFECT | Filing | Jun 24, 2026 | — |
| RW | Filing | Jun 5, 2026 | — |
| CORRESP | Letter to the SEC | Aug 11, 2025 | — |
| CORRESP | Letter to the SEC | Aug 8, 2025 | — |
| CORRESP | Letter to the SEC | Aug 8, 2025 | — |
| CORRESP | Letter to the SEC | Aug 7, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 6, 2025 | — |
| CORRESP | Letter to the SEC | May 22, 2025 | — |
| UPLOAD | Letter from the SEC | May 1, 2025 | — |
| CORRESP | Letter to the SEC | Apr 16, 2025 | — |
| UPLOAD | Letter from the SEC | Feb 19, 2025 | — |
| EFFECT | Filing | Dec 27, 2024 | — |
| D | Filing | Dec 27, 2024 | — |
| CORRESP | Letter to the SEC | Dec 26, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 18, 2024 | — |
| DFAN14A | Form dfan14a | Mar 20, 2024 | — |
| EFFECT | Filing | Jun 6, 2023 | — |
| CORRESP | Letter to the SEC | Jun 2, 2023 | — |
| UPLOAD | Letter from the SEC | Jun 1, 2023 | — |
| D | Filing | May 25, 2023 | — |
| EFFECT | Filing | Aug 16, 2022 | — |
| CORRESP | Letter to the SEC | Aug 12, 2022 | — |
| UPLOAD | Letter from the SEC | Aug 10, 2022 | — |
| EFFECT | Filing | Jun 23, 2022 | — |
| CORRESP | Letter to the SEC | Jun 21, 2022 | — |
| UPLOAD | Letter from the SEC | Jun 21, 2022 | — |
| UPLOAD | Letter from the SEC | May 9, 2022 | — |
| CORRESP | Letter to the SEC | May 6, 2022 | — |
| D | Filing | May 5, 2022 | — |
| UPLOAD | Letter from the SEC | Apr 22, 2022 | — |
| EFFECT | Filing | Feb 1, 2021 | — |
| CORRESP | Letter to the SEC | Jan 28, 2021 | — |
| UPLOAD | Letter from the SEC | Jan 20, 2021 | — |
| EFFECT | Filing | Feb 6, 2020 | — |
| CORRESP | Letter to the SEC | Feb 5, 2020 | — |
| CORRESP | Letter to the SEC | Feb 5, 2020 | — |
| UPLOAD | Letter from the SEC | Jan 14, 2020 | — |
| 425 | Filing | Jul 18, 2019 | — |
| 425 | 8-k | Jul 15, 2019 | — |
| 425 | Filing | Jul 12, 2019 | — |
| 425 | Form 8-k | Jul 1, 2019 | — |
| 425 | Filing | Jun 26, 2019 | — |
| 425 | Filing | Jun 25, 2019 | — |
| 425 | Filing | Jun 19, 2019 | — |
| 425 | Filing | Jun 17, 2019 | — |
| 425 | 8-k | Jun 14, 2019 | — |
| 425 | Filing | Jun 10, 2019 | — |
| 425 | Filing | Jun 10, 2019 | — |
| 425 | Filing | Jun 6, 2019 | — |
| 425 | Filing | May 31, 2019 | — |
| 425 | Filing | May 28, 2019 | — |
| 425 | Filing | May 22, 2019 | — |
| EFFECT | Filing | May 17, 2019 | — |
| 425 | Filing | May 17, 2019 | — |
| CORRESP | Letter to the SEC | May 16, 2019 | — |
| 425 | Filing | May 16, 2019 | — |
| 425 | Filing | May 10, 2019 | — |
| 425 | Filing | May 10, 2019 | — |
| UPLOAD | Letter from the SEC | Apr 30, 2019 | — |
| EFFECT | Filing | Apr 29, 2019 | — |
| CT ORDER | Filing | Apr 29, 2019 | — |
| CORRESP | Letter to the SEC | Apr 25, 2019 | — |
| CORRESP | Letter to the SEC | Apr 17, 2019 | — |
| UPLOAD | Letter from the SEC | Apr 15, 2019 | — |
| CORRESP | Letter to the SEC | Mar 26, 2019 | — |
| UPLOAD | Letter from the SEC | Mar 18, 2019 | — |
| 425 | 8-k | Jan 4, 2019 | — |
| CT ORDER | Filing | Aug 30, 2016 | — |
| CT ORDER | Filing | Jun 15, 2016 | — |
| EFFECT | Filing | Apr 26, 2016 | — |
| CORRESP | Letter to the SEC | Apr 22, 2016 | — |
| UPLOAD | Letter from the SEC | Mar 30, 2016 | — |
| CT ORDER | Filing | Jan 19, 2016 | — |
| EFFECT | Filing | Jan 28, 2015 | — |
| CORRESP | Letter to the SEC | Jan 26, 2015 | — |
| CORRESP | Letter to the SEC | Jan 26, 2015 | — |
| CERTNAS | Auto-generated paper document | Jan 26, 2015 | — |
| CORRESP | Letter to the SEC | Jan 23, 2015 | — |
| 8-A12B | Filing | Jan 23, 2015 | — |
| CORRESP | Letter to the SEC | Jan 22, 2015 | — |
| CORRESP | Letter to the SEC | Jan 22, 2015 | — |
| CORRESP | Letter to the SEC | Jan 7, 2015 | — |
| CORRESP | Letter to the SEC | Dec 29, 2014 | — |
| UPLOAD | Letter from the SEC | Dec 19, 2014 | — |
| DRSLTR | Filing | Dec 8, 2014 | — |
| DRS/A | Filing | Dec 8, 2014 | — |
| UPLOAD | Letter from the SEC | Nov 26, 2014 | — |
| DRS | Filing | Oct 29, 2014 | — |
| D | Filing | Aug 6, 2014 | — |
Showing 91 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- DCOY (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Houston, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1615219
- Former names
- Salarius Pharmaceuticals, Inc. (until Jan 9, 2026); Flex Pharma, Inc. (until Jul 22, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.